Skip to main content
SpringerLink
Log in

Development of platelet contractile force as a research and clinical measure of platelet function

  • Review Article
  • Published:
Cell Biochemistry and Biophysics Aims and scope Submit manuscript

Abstract

This article reviews work performed at the Medical College of Virginia of Virginia Commonwealth University during the development of a whole-blood assay of platelet function. The new assay is capable of assessing platelet function during clotting and thus allows measurement of the contribution of platelets to thrombin generation. Because platelets are monitored in the presence of thrombin, the test gages platelets under conditions of maximal activation. Three parameters are simultaneously assessed on one 700-μL sample of citrated whole blood. Platelet contractile force (PCF), the force produced by platelets during clot retraction, is directly measured as a function of time. This parameter is sensitive to platelet number, platelet metabolic status, glycoprotein IIb/IIIa status, and the presence of antithrombin activities. Clot elastic modulus (CEM), also measured as a function of time, is sensitive to fibrinogen concentration, platelet concentration, the rate of thrombin generation, the flexibility of red cells, and the production of force by platelets. The third parameter, the thrombin generation time (TGT) is determined from the PCF kinetics curve. Because PCF is absolutely thrombin dependent (no thrombin—no force), the initial upswing in PCF occurs at the moment of thrombin production. TGT is sensitive to clotting factor deficiencies, clotting factor inhibitors, and the presence of antithrombins, all of which prolong the TGT and are known to be hemophilic states. Treatment of hemophilic states with hemostatic agents shortens, the TGT toward normal. TGT has been demonstrated to be shorter and PCF to be increased in coronary artery disease, diabetes mellitus, and several other thrombophilic states. Treatment of thrombophilic states with a variety of heparin and nonheparin anticoagulants prolongs the TGT toward normal. The combination of PCF, CEM, and TGT measured on the same sample may allow rapid assessment of global hemostasis and the response to a variety of procoagulant and anticoagulant medications.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Quick, A. J., Stanley-Brown, M., and Bancroft, F. W. (1935) A study of the coagulation defect in hemophilia and in jaundice. Am. J. Med. Sci. 190, 501–511.

    Google Scholar 

  2. Proctor, R. R., and Rappaport, S. I. (1961) The partial thromboplastin time with kaolin. A simple screening test for first stage plasma clotting factor deficiencies. Am. J. Clin. Pathol. 36, 212–219.

    PubMed  CAS  Google Scholar 

  3. Matchett, M. O. and Ingram, G. I. C. (1965) Partial thromboplastin time test with kaolin. Normal range and modifications for the diagnosis of haemophilia and Christmas disease. J. Clin. Pathol. 18, 465.

    Article  PubMed  CAS  Google Scholar 

  4. Gaydos, L. A., Freireich, E. J., and Mantel, N. (1962) The quantitative relation between platelet count and hemorrhage in individuals with acute leukemia. N. Engl. J. Med. 266, 905–909.

    Article  PubMed  CAS  Google Scholar 

  5. Ivy, A. C., Shapiro, P. F., and Melnick, P. (1935) The bleeding tendency in jaundice. Surg. Gynecol. Obstet. 60, 781–784.

    Google Scholar 

  6. Ivy, A. C., Nelson, D., and Bucher, G. (1941) The standardization of certain factors in the cutaneous “venostasis” bleeding time technique. J. Lab. Clin. Med. 26, 1812–1822.

    Google Scholar 

  7. Mielke, C. H., Jr, Kaneshiro, M. M., Maher, I. A. et al. (1969) The standardized normal Ivy bleeding time and its prolongation by aspirin. Blood 34, 204–215.

    PubMed  Google Scholar 

  8. Rogers, R. P. C., Levin, J. (1990) A critical reappraisal of the bleeding time. Semin. Thromb. Hemost. 16, 1–20.

    Article  Google Scholar 

  9. Lind, S. E. (1991) The bleeding time does not predict surgical bleeding. Blood 77, 2547–2552.

    PubMed  CAS  Google Scholar 

  10. Koster, T., Caekebeke-Peerlinck, K. M., and Briet, E. (1989) A randomized, and blinded comparison of the sensitivity and the reporducibility of the Ivy and Simplate II bleeding time techniques. Am. J. Clin. Pathol. 92, 315–320.

    PubMed  CAS  Google Scholar 

  11. Schwartz, L., Brister, S. J., Bourassa, M. G., Peniston, C., and Buchanan, M. R. (1998) Interobserver reproducibility and biological variability of the surgicutt II bleeding time. J. Thromb. Thrombolysis 6, 155–158.

    Article  PubMed  Google Scholar 

  12. O'Brien, J. R. (1962) Platelet aggregation. II. Some results from a new method of study. J. Clin. Pathol. 15, 452–455.

    Article  Google Scholar 

  13. Born, G. V. and Cross, M. J. (1963) The aggregation of blood platelets. J. Physiol. 168, 178–195.

    PubMed  CAS  Google Scholar 

  14. Simon, D. I., Liu, C. B., Ganz, P., et al. (2001) A comparative study of light transmission aggregometry and automated bedside platelet function assays in patients undergoing percutaneous coronary intervention and receiving abciximab, eptifibatide, or tirofiban. Cathet. Cardiovasc. Intervent. 52, 425–432.

    Article  CAS  Google Scholar 

  15. Storey, R. F., May, J. A., Wilcox, R. G., and Heptinstall, S. (1999) A whole blood assay of inhibition of platelet aggregation by glycoprotein IIb/IIIa antagonists: comparison with other aggregation methodologies. Thromb. Haemost. 82, 1307–1311.

    PubMed  CAS  Google Scholar 

  16. Smith, J. W., Steinhubl, S. R., Lincoff, A. M., et al. (1999) Rapid platelet-function assay: an automated and quantitative cartridge-based method. Circulation 99, 620–625.

    PubMed  CAS  Google Scholar 

  17. Madan, M., Berkowitz, S. D., Christie, D. J., Smith, A. C., Sigmon, K. N., and Tcheng, J. E. (2002) Determination of platelet aggregation inhibition during percutaneous coronary intervention with the platelet function analyzer PFA-100. Am. Heart J. 144, 151–158.

    Article  PubMed  CAS  Google Scholar 

  18. Salat, A., Kroess, S., Felfernig-Boehm, D., et al. (2002) Comparison of in vitro closure time (PFA-100) with whole blood electrical aggregometry and platelet surface antigen expression in healthy volunteers. Thromb. Res. 105, 205–208.

    Article  PubMed  CAS  Google Scholar 

  19. Glanzmann, E. (1918) Hereditäre hämorrhagische thrombasthenie. Ein Beitrag zur Pathologie der Blutplättchen. Jahr. Kinderheilk. 88, 1–42.

    Google Scholar 

  20. Budtz-Olsen, O. E. (1951) Clot Retraction. Blackwell, Oxford.

    Google Scholar 

  21. Carr, M. E. and Zekert, S. L. (1991) Measurement of platelet mediated-force development during plasma clot formation. Am. J. Med. Sci. 302, 13–18.

    Article  PubMed  Google Scholar 

  22. Cohen, I. and De Vries, A. (1973) Platelet contractile regulation in an isometric system. Nature 246, 36–37.

    Article  PubMed  CAS  Google Scholar 

  23. Carr, M. E., and Zekert, S. L. (1989) Platelet mediated clot retraction is temperature dependent—studies with a new retractometer. Blood 74(Suppl. 1), 399a.

    Google Scholar 

  24. Carr, M. E., Zekert, S. L. (1991) Force monitoring of clot retraction during DDAVP therapy for the qualitative platelet disorder of uraemia: Report of a case. Blood Coagul. Fibrinol. 2, 303–308.

    Google Scholar 

  25. Carr, M. E., Zekert, S. L., Marston, A. W., Magruder, C., and Kirschbaum, B. (1994) Comparison of platelet force development, a new measure of platelet function, and bleeding time in chronic hemodialysis patients. Am. J. Clin. Pathol. 101, 392 (abstract).

    Google Scholar 

  26. Carr, M. E., Shen, L. L., and Hermans, J. (1976) A physical standard of fibrinogen: measurement of the elastic modulus of dilute fibrin gels with a new elastometer. Anal. Biochem. 72, 202–211.

    Article  PubMed  CAS  Google Scholar 

  27. Carr, M. E. and Carr, S. L. (1995) Fibrin structure and concentration alter clot elastic modulus but do not alter platelet mediated force development. Blood Coag. Fibrinol. 6, 79–86.

    CAS  Google Scholar 

  28. Carr, M. E., Zekert, S. L., and Jolly, M. K. (1992) Whole blood clot elastic modulus as a measure of altered erthrocyte flexibility in sickle cell disease. Blood 80(Suppl. 1), 11a.

    Google Scholar 

  29. Carr, M. E., Carr, S. L., and McCardell, K. A. (1996) Use of TPA-induced clot lysis time (LCLOT) to diagnosis abnormal clot structure and fibrinolysis in a patient with spontaneous bleeding into his leg. Angiology 47, 941–949.

    PubMed  Google Scholar 

  30. Carr, M. E., Carr, S. L., Massey, G., and Trent, D. (1994) Successful application of the tPA-induced clot lysis time (tCLT) in three patients with previously undiagnosed bleeding diathesis. Blood 84(Suppl. 1), 674a.

    Google Scholar 

  31. Carr, M. E. (1995) Measurement of platelet force: the Hemodyne® Hemostatic Analyzer. Clin. Lab. Manag. Rev. 9, 312–320.

    CAS  Google Scholar 

  32. Harker, L. A. (1986) Bleeding after cardiopulmonary bypass. N. Engl. J. Med. 314, 1446–1448.

    Article  PubMed  CAS  Google Scholar 

  33. Woodman, R. C. and Harker, L. A. (1990) Bleeding complications associated with cardiopulmonary bypass. Blood 76, 1680–1697.

    PubMed  CAS  Google Scholar 

  34. Harker, L., Malpass, T. W., Branson, H. E., et al. (1980) Mechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass: acquired transient platelet dysfunction associated with selective alpha-granule release. Blood 56, 824–834.

    PubMed  CAS  Google Scholar 

  35. Greilich, P. E., Carr, M. E., Carr, S. L., and Chang, A. S. (1995) Reductions in platelet force development by cardiopulmonary bypass are associated with hemorrhage. Anesth. Analg. 80, 459–465.

    Article  PubMed  CAS  Google Scholar 

  36. George, J. N., Pickett, E. B., Saucerman, S., et al. (1986) Platelet surface glycoproteins. Studies on resting and activated platelet and platelet membrane microparticles in normal subjects, and observations in patients during adult respiratory distress syndrome and cardiac surgery. J. Clin. Invest. 78, 340–348.

    PubMed  CAS  Google Scholar 

  37. Wenger, R. K., Lukasiewicz, H., Mikuta, B. S., et al. (1989) Loss of platelet fibrinogen receptors during clinical cardiopulmonary bypass. J. Thorac. Cardiovasc. Surg. 97, 235–239.

    PubMed  CAS  Google Scholar 

  38. Rinder, C. S., Mathew, J. P., Rinder, H. M., et al. (1991) Modulation of platelet surface adhesion receptors during cardiopulmonary bypass. Anesthesiology 75, 563–570.

    Article  PubMed  CAS  Google Scholar 

  39. Carr, M. E. and Carr, S. L. (1994) At high heparin concentrations, protamine concentrations which reverse heparin anticoagulant effects are insufficient to reverse heparin anti-platelet effects. Thromb. Res. 75, 617–630.

    Article  PubMed  CAS  Google Scholar 

  40. Carr, M. E. and Martin, E. J. (1999) Reproducibility, daily variation, and the effect of sample age on platelet contractile force and clot elastic modulus in normal volunteers. Thromb. Haemost. 74(Suppl.), 396.

    Google Scholar 

  41. Alving, B. M., Reid, T. J., Fratantoni, J. C., and Finlayson, J. S. (1997) Frozen platelets and platelet substitutes in transfusion medicine. Transfusion 37, 866–876.

    Article  PubMed  CAS  Google Scholar 

  42. Reid, T., Snider, R., Hartman, K., Greilich, P. E., Carr, M. E., and Alving, B. M. (1998) A method for the quantitative assessment of platelet-induced clot retraction and clot strength in fresh and stored platelets. Vox Sanguinis 75, 270–277.

    Article  PubMed  CAS  Google Scholar 

  43. de Gaetano, G., Franco, R., Donati, M. B., Bonaccorsi, A., and Garattini, S. (1974) Mechanical recording of reptilase-clot retraction: effect of adenosine-5′-diphosphate and prostaglandin E1. Thromb. Res. 4, 189–192.

    Article  PubMed  Google Scholar 

  44. Carr, M. E., Carr, S. L., and Greilich, P. E. (1996) Heparin ablates force development during platelet mediated clot retraction. Thromb. Haemost. 75, 674–678.

    PubMed  CAS  Google Scholar 

  45. Carr, M. E., Jr., Angchaisuksiri, P., Carr, S. L., and Barnes, J. (1995) Effect of antithrombin III concentrate, alone or with heparin, on clot structure and platelet function. Blood 86 (Suppl. 1), 866a.

    Google Scholar 

  46. Carr, M. E., Park, A., Zekert, S. L., Marques, D., Goldman, I. D., and Sobel, M. (1993) Anticoagulant and antiplatelet activities of heparin and low molecular weight derivatives. Blood 82 (Suppl. 1) 603a.

    Google Scholar 

  47. Carr, M. E., Monge-Meberg, P., McCardell, K., and Carr, S. L. (1996) Dermatan sulfate suppresses platelet force as it prolongs the APTT. Blood 88 (Suppl. 1), 79b.

    Google Scholar 

  48. Carr, M. E. and Zekert, S. (1993) Effect of non-heparin thrombin antagonists on platelet force development during clot retraction. Thromb. Haemost. 69, 1241.

    Google Scholar 

  49. Carr, M. E., Carr, S. L., Tildon, T., Fisher, L. M., and Martin, E. J. (2003) Batroxobin-induced clots exhibit delayed and reduced platelet contractile force in some patients with clotting factor deficiencies. J. Thromb. Haemost. 1, 243–249.

    Article  PubMed  CAS  Google Scholar 

  50. Erickson, B. and Macik, B. G. (1999) Platelet contractile force in chronic hemodialysis patients with arterial-venous fistula. Blood 94 (Suppl. 1), (abstract) 79b.

    Google Scholar 

  51. Greilich, P. E., Carr, M. E., Zekert, S. L., and Dent, R. M. (1994) Quantitative assessment of platelet function and clot structure in patients with severe coronary artery disease. Am. J. Med. Sci. 307, 15–20.

    Article  PubMed  CAS  Google Scholar 

  52. Krishnaswami, A., Carr, M. E., Jessie, R. L., et al. (2002) Patients with coronary artery disease who present with chest pain have significantly elevated platelet contractile force and clot elastic modulus. Thromb. Haemost. 88, 739–744.

    PubMed  CAS  Google Scholar 

  53. Carr, M. E., Krishnaswami, A., and Martin, E. J. (2002) Platelet contractile force (PCF) and clot elastic modulus (CEM) are elevated in diabetic patients with chest pain. Diabet. Med. 19, 862–866.

    Article  PubMed  CAS  Google Scholar 

  54. Carr, M. E., Hackney, M. H., Hines, S. J., Heddinger, S. P., Carr, S. L., and Martin, E. J. (2002) Enhanced platelet force development despite drug induced inhibition of platelet aggregation in patients with thromboangiitis obliterans. Vasc. Endovasc. Surg. 36, 473–480.

    Google Scholar 

  55. Carr, M. E. and Zekert, S. L. (1994) Abnormal clot retraction, altered fibrin structure, and normal platelet function in multiple myeloma. Am. J. Physiol. 266, H1195-H1201.

    PubMed  CAS  Google Scholar 

  56. Carr, M. E. (2001) Diabetes mellitus, a hypercoagulable state. J. Diabetes Complic. 15, 44–54.

    Article  CAS  Google Scholar 

  57. Collier, A., Rumley, A., Rumley, A. G., et al. (1992) Free radical activity and hemostatic factors in NIDDM patients with and without microalbuminuria. Diabetes 41, 909–913.

    Article  PubMed  CAS  Google Scholar 

  58. Carmassi, F., Morale, M., Puccetti, R., et al. (1992) Coagulation and fibrinolytic system impairment in insulin dependent diabetes mellitus. Thromb. Res. 67, 643–654.

    Article  PubMed  CAS  Google Scholar 

  59. Borsey, D. Q., Prowse, C. V., Gray, R. S., et al. (1984) Platelet and coagulation factors in proliferative diabetic retinopathy. J. Clin. Pathol. 37, 659–664.

    Article  PubMed  CAS  Google Scholar 

  60. Carr, M., Jones, C., Adler, R., Dent, R., and Carr, S. (2001) Hyperglycemia alters fibrinogen leading to abnormal fibrin structures and delayed fibrinolysis in diabetes. Thromb. Haemost. (Suppl.) (abstract) 86, P1255.

    Google Scholar 

  61. Carr, M. E., Dent, R. M., and Carr, S. L. (1996) Abnormal fibrin structure and inhibition of fibrinolysis in patients with multiple myeloma. J. Lab. Clin. Med. 128, 83–88.

    Article  PubMed  CAS  Google Scholar 

  62. Carr Jr., M. E., Angchaisuksiri, P., and Carr, S. L. (1995) Effect of ε-aminocap roic acid (EACA) on clot structure and platelet function during tPA mediated clot dissolution. Blood 86(Suppl. 1), 895a.

    Google Scholar 

  63. Reverter, J. C., Beguin, S., Kessels, H., Kumar, R., Hemmer, H. C., and Coller, B. S. (1996) Inhibition of platelet-mediated, tissue-factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody; potential implications for the effect of 7E3 Fab treatment on acute thrombosis and “clinical restenosis”. J. Clin. Invest. 98, 863–874.

    Article  PubMed  CAS  Google Scholar 

  64. EPIC Investigators. (1994) Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N. Engl. J. Med. 330, 956–961.

    Article  Google Scholar 

  65. EPILOG Investigators. (1997) Platelet glycoprotein IIb/IIIa receptor blockade and low dose heparin during percutaneous coronary revascularization. N. Engl. J. Med. 336, 1689–1696.

    Article  Google Scholar 

  66. Carr, M. E., Carr, S. L., Hantgan, R. R., and Braaten, J. (1995) Glycoprotein IIb/IIIa blockade inhibits platelet mediated force development and reduces gel elastic modulus. Thromb. Haemost. 73, 499–505.

    PubMed  CAS  Google Scholar 

  67. Greilich, P. E., Alving, B. M., O'Neill, K. L., Chang, A. S., and Reid, T. J. (1997) A modified thromboelastographic method for monitoring c7E3 Fab in heparinized patients. Anesthet. Analg. 84, 31–38.

    Article  CAS  Google Scholar 

  68. Greilich, P. E., Alving, B. M., Longnecker, D., et al. (1999) Near-site monitoring of the antiplatelet drug ABCIXIMAB using the Hemodyne® analyzer and modified Thromboelastograph®. J. Cardiothorac. Vasc. Anesth. 13, 58–64.

    Article  PubMed  CAS  Google Scholar 

  69. The Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. (1998) A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N. Engl. J. Med. 338, 1498–1505.

    Article  Google Scholar 

  70. The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs, and Symptoms (PRISM-PLUS) Study Investigators. (1998) Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave infarction. N. Engl. J. Med. 338, 1488–1497.

    Google Scholar 

  71. The PURSUIT Trial Investigators. (1998) Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. Platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy. N. Engl. J. Med. 339, 436–443.

    Article  Google Scholar 

  72. The IMPACT II Investigators. (1997) Randomized placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to minimize platelet aggregation and coronary thrombosis-II. Lancet 349, 1422–1428.

    Article  Google Scholar 

  73. McCardell, K. A., Carr, S. L., and Carr, M. E. (1996) Aprotinin augments protamine sulfate reversal of heparin antiplatelet effects. J. Invest. Med. 44, 212A.

    Google Scholar 

  74. Carr Jr., M. E., Carr, S., and Roa, V. (1996) Aprotinin prevents heparin blockade of platelet force development. Experimental Biology '96—The American Physiology Society.

  75. McCardell, K. A., Carr, S. L., and Carr, M. E. (1996) Aprotinin can reverse heparin mediated suppression of platelet force development. J. Invest. Med. 44, 287A.

    Google Scholar 

  76. Carr, M. E., Carr, S. L., McCardell, K., and Dessypris, E. N. (1997) Differential effects of thrombopoietin and stem cell factor on platelet contractile force. Blood 90 (Suppl. 1) 67b.

    Google Scholar 

  77. Carr, M. E. (1997) In vitro assessment of platelet function. Transfusion Med. Rev. 11, 106–115.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Coagulation Special Studies Laboratory, Division of Hematology/Oncology, Central Virginia Center for Coagulation Disorders, Departments of Medicine and Pathology, Medical College of Virginia, Virginia Commonwealth University, 23298, Richmond, VA

    Marcus E. Carr Jr.

  2. Richmond Veterans Administration Medical Center, 23298, Richmond, VA

    Marcus E. Carr Jr.

Authors
  1. Marcus E. Carr Jr.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marcus E. Carr Jr..

Rights and permissions

Reprints and permissions

About this article

Cite this article

Carr, M.E. Development of platelet contractile force as a research and clinical measure of platelet function. Cell Biochem Biophys 38, 55–78 (2003). https://doi.org/10.1385/CBB:38:1:55

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1385/CBB:38:1:55

Index Entries

Search

Navigation